Aktis Oncology: Buy the Radiotherapeutics Platform Ahead of Clinical Readouts
Aktis Oncology is a clinical-stage radiopharmaceutical company with a deep-pocketed IPO and a pipeline built around miniprotein radioconjugates designed to reach large patient populations. Recent IND clearance activity and first clinical imaging/dosimetry data for AKY-2519 set up a series of binary catalysts. At a market cap near $990M and with ~ $…